BPA for cinryze, kalbitor, gattex, natpara
Ended Awarded Last action
- Contract number
- 36E79720A0014
- Awardee
-
Takeda Pharmaceuticals America, Inc. UEI DDEVYUAXJ624 Part of Takeda Pharmaceutical Company LIMITED
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 100% complete
- IDV ceiling
- $19,472,334.90
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
The U.S. Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Blanket Purchase Agreement (BPA) to Takeda Pharmaceuticals America Inc. in July 2020. The $19,472,334.90 BPA, which falls under Takeda's General Services Administration (GSA) Pharmaceutical and Drugs Schedule contract, facilitates the streamlined procurement of critical specialty pharmaceutical products for the VA healthcare system. Key products under this BPA include CINRYZE and KALBITOR for hereditary angioedema, GATTEX for short bowel syndrome, and NATPARA for hypocalcemia. This 4-year agreement enables the VA to efficiently order these specialized treatments, ensuring consistent access for eligible veteran patients. As a subsidiary of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America Inc. primarily supplies specialty drugs to various U.S. government agencies, including the Department of Veterans Affairs, Department of Justice Bureau of Prisons, and Department of Defense. The company leverages its parent's international infrastructure to deliver these critical medications to federal facilities nationwide.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Show all 20
Quick answers
Who was awarded contract 36E79720A0014?
36E79720A0014 was awarded to Takeda Pharmaceuticals America, Inc. by National Acquisition Center (Headquarters) on July 15, 2020.
How much is contract 36E79720A0014 worth?
36E79720A0014's own ceiling is $19,472,335.
Who can order from contract 36E79720A0014?
36E79720A0014 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79720A0014 under another contract?
Yes. 36E79720A0014 is a blanket purchase agreement under V797D50492, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79720A0014 competed?
The extent of competition for 36E79720A0014 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV